Trial Profile
A Phase 1 Study of AEB071, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2021
Price :
$35
*
At a glance
- Drugs Sotrastaurin (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.
- 31 Jan 2019 Planned End Date changed from 11 Oct 2018 to 10 May 2019.
- 31 Jan 2019 Planned primary completion date changed from 11 Oct 2018 to 10 May 2019.